Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

alpha4-Integrin antagonism with natalizumab: effects and adverse effects.

Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC.

J Neurol. 2008 Dec;255 Suppl 6:58-65. doi: 10.1007/s00415-008-6011-0. Review.

PMID:
19300961
2.

The effects of natalizumab on the innate and adaptive immune system in the central nervous system.

Stüve O.

J Neurol Sci. 2008 Nov 15;274(1-2):39-41. doi: 10.1016/j.jns.2008.03.022. Review.

PMID:
18474372
3.

Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.

Johnson KP.

Neurologist. 2007 Jul;13(4):182-7. Review.

PMID:
17622909
4.
5.

Natalizumab: targeting alpha4-integrins in multiple sclerosis.

Engelhardt B, Kappos L.

Neurodegener Dis. 2008;5(1):16-22. Review.

PMID:
18075270
6.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Rudick RA, Sandrock A.

Expert Rev Neurother. 2004 Jul;4(4):571-80. Review.

PMID:
15853576
7.

Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.

Lanzarotto F, Carpani M, Chaudhary R, Ghosh S.

Drugs. 2006;66(9):1179-89. Review.

PMID:
16827596
8.

[Natalizumab in the treatment of multiple sclerosis].

Horga A, Horga de la Parte JF.

Rev Neurol. 2007 Sep 1-15;45(5):293-303. Review. Spanish.

9.

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.

O'Connor P.

Expert Opin Biol Ther. 2007 Jan;7(1):123-36. Review.

PMID:
17150024
10.

Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.

Ko HH, Bressler B.

Expert Rev Gastroenterol Hepatol. 2007 Oct;1(1):29-39. doi: 10.1586/17474124.1.1.29. Review.

PMID:
19072431
11.

Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Langer-Gould A, Steinman L.

Curr Neurol Neurosci Rep. 2006 May;6(3):253-8. Review.

PMID:
16635435
12.

Natalizumab.

Berger JR.

Drugs Today (Barc). 2006 Oct;42(10):639-55. Review.

PMID:
17136224
13.

Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.

[No authors listed]

Drugs R D. 2004;5(2):102-7. Review.

PMID:
15293871
14.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Aksamit AJ.

Neurologist. 2006 Nov;12(6):293-8. Review.

PMID:
17122725
15.

Natalizumab for relapsing-remitting multiple sclerosis.

Horga A, Tintoré M.

Neurologia. 2011 Jul-Aug;26(6):357-68. doi: 10.1016/j.nrl.2010.10.004. Review. English, Spanish.

16.

[Blocking adhesion molecules with natalizumab in multiple sclerosis].

Schreiner B, Kieseier BC, Hartung HP, Hohlfeld R, Wiendl H.

Nervenarzt. 2005 Aug;76(8):999-1005. Review. German.

PMID:
15812675
17.

Progressive multifocal leukoencephalopathy and natalizumab.

Hellwig K, Gold R.

J Neurol. 2011 Nov;258(11):1920-8. doi: 10.1007/s00415-011-6116-8. Review.

PMID:
21647730
18.

[New drugs; natalizumab].

van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF.

Ned Tijdschr Geneeskd. 2008 Mar 1;152(9):499-500. Review. Dutch.

PMID:
18389881
19.

Natalizumab update.

Sweet BV.

Am J Health Syst Pharm. 2007 Apr 1;64(7):705-16. Review.

PMID:
17384355
20.

The role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implications.

Sheremata WA, Minagar A, Alexander JS, Vollmer T.

CNS Drugs. 2005;19(11):909-22. Review.

PMID:
16268663

Supplemental Content

Support Center